| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,173 | 3,286 | 3,333 | 3,653 | 3,791 | 3,643 | 3,560 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,217 | 2,383 | 2,401 | 2,724 | 2,776 | 2,754 | 2,536 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 956 | 903 | 933 | 930 | 1,016 | 889 | 1,024 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % | 25 % | 23 % | 26 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 101 | 187 | 231 | 219 | 222 | 223 | 223 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 | 624 | 509 | 659 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 | 104 | 95 | 100 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 | 12.39 | 9.90 | 13.44 |
Mankind Pharma
Mankind Pharma
2,398.00
+21.80
(0.92%)
Market Cap
98,990.66 Cr
PE Ratio
50.54
Volume
1,05,654.00
Day High - Low
2,408.00 - 2,350.50
52W High-Low
2,716.50 - 1,909.70
Key Fundamentals
Market Cap
98,990.66 Cr
EPS
46.35
PE Ratio
50.54
PB Ratio
6.01
Book Value
394.69
EBITDA
3,487.60
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
13.77
Debt to Equity
0.37
Analyst Rating and Forecast
- By Refinitiv from18 analysts
Actual
Company News
View All News
Promoters of Mankind Pharma confirmed no encumbrance on shares for FY26 under SEBI regulations.
Mankind Pharma Limited has appointed Mr. Nilesh Kulkarni as the Head of Human Resource Functions and designated him as a Senior Management Personnel effective June 8, 2026. This follows an internal organizational restructuring.
Jefferies Maintains Buy on Mankind Pharma, TP ₹3,0008 days ago
Jefferies reiterates Buy rating on Mankind Pharma with a target price of ₹3,000, backed by double-digit India growth, high-teens export expansion, and R&D upside.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,791.80 | #1 4,29,912.84 | 37.25 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 45.08 | |
6,703.00 | 1,77,943.59 | 68.63 | 10,560.00 | 8.73 | 2,520 | 13.44 | 50.39 | |
4,580.00 | 1,55,008.01 | 70.64 | 13,886.20 | 20.34 | 2,138 | -26.91 | 55.63 | |
1,383.10 | 1,11,724.15 | 28.79 | 29,044.60 | 2.24 | 3,870 | -55.32 | 51.44 | |
1,102.50 | 1,10,937.30 | 21.56 | 26,719.70 | 13.65 | 5,242 | 7.82 | 70.28 | |
1,280.70 | 1,06,892.73 | 25.53 | 33,593.30 | -0.44 | 3,998 | -86.05 | 44.45 | |
2,258.10 | 1,03,204.93 | #1 19.20 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 43.65 | |
2,398.00 | #8 98,990.66 | #7 50.54 | #7 14,277.60 | #5 12.03 | #9 1,750 | #2 31.75 | 51.33 | |
1,463.70 | 85,011.93 | 24.11 | 33,384.70 | 3.21 | 3,376 | 1.99 | 51.56 | |
1,395.30 | 75,326.19 | 84.04 | 6,812.90 | #1 21.03 | 884 | 21.18 | 61.02 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
12.03 %
Net Income Growth
-12.80 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
-14.63 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Fixed Assets | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 13,256 |
| Current Assets | 3,907 | 4,407 | 4,328 | 6,568 | 6,988 | 6,954 |
| Capital Work in Progress | 372 | 702 | 550 | 282 | 826 | 655 |
| Investments | 1,512 | 1,110 | 1,346 | 2,568 | 2,042 | 2,145 |
| Other Assets | 2,824 | 3,749 | 3,568 | 4,568 | 5,887 | 0 |
| Total Equity & Liabilities | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Current Liabilities | 1,353 | 2,624 | 1,863 | 2,120 | 5,664 | 6,507 |
| Non Current Liabilities | 156 | 208 | 229 | 268 | 7,528 | 5,011 |
| Total Equity | 4,863 | 6,316 | 7,623 | 9,576 | 14,568 | 16,300 |
| Reserve & Surplus | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Share Capital | 40 | 40 | 40 | 40 | 41 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % | 72.67 % | 72.66 % | 72.66 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % | 12.84 % | 11.34 % | 10.24 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % | 11.92 % | 13.25 % | 14.46 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % | 1.36 % | 1.52 % | 1.39 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % | 1.21 % | 1.23 % | 1.25 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 |  Quarterly Result Announcement | NA | 05 Nov 2024 | 2,504.25 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,432.40 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.50 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,384.70 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.50 | 2,537.80 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,432.40 | 2,369.35 |
| 03 Feb 2026 | Quarterly Result Announcement | NA | 03 Feb 2026 | 2,261.20 | 2,063.80 |
| 19 May 2026 | Quarterly Result Announcement | NA | 19 May 2026 | 2,361.90 | 2,496.35 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Acquisition8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-AcquisitionMay 19, 2026
May 19, 2026Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31 2026May 19, 2026
May 19, 2026Financial Results For The Quarter And Financial Year Ended March 31 2026May 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Credit RatingMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2026
May 08, 2026Board Meeting Intimation for Inter Alia Consider And Approve The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31 2026 And Realignment Of Security Cover Provided In Respect Of ExistiMay 07, 2026
May 07, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2026
May 06, 2026Announcement under Regulation 30 (LODR)-Credit RatingApr 22, 2026
Apr 22, 2026Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD Apr 16, 2026
Apr 16, 2026Announcement under Regulation 30 (LODR)-RestructuringApr 13, 2026
Apr 13, 2026Board Meeting Outcome for Outcome Of Board MeetingApr 13, 2026
Apr 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2026
Mar 18, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 16, 2026
Mar 16, 2026Clarification Submitted By Mankind Pharma LimitedFeb 27, 2026
Feb 27, 2026Clarification sought from Mankind Pharma LtdFeb 27, 2026
Feb 27, 2026Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Credit RatingFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Feb 18, 2026Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 16, 2026
Feb 16, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2026
Feb 03, 2026Compliances-Reg. 54 - Asset Cover details Feb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2026
Feb 03, 2026Board Meeting Outcome for Outcome Of Board Meeting Of Financial Results For Q3 FY26Feb 03, 2026
Feb 03, 2026Financial Result For The Quarter And Nine Months Ended December 31 2025Feb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Credit RatingJan 16, 2026
Jan 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 16, 2026
Jan 16, 2026Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The CompanyJan 09, 2026
Jan 09, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Jan 05, 2026Closure of Trading WindowDec 24, 2025
Dec 24, 2025Closure of Trading WindowDec 24, 2025
Dec 24, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Dec 10, 2025
Dec 10, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 51.33
ATR(14)
Less Volatile 70.59
STOCH(9,6)
Neutral 38.33
STOCH RSI(14)
Neutral 28.51
MACD(12,26)
Bearish -15.85
ADX(14)
Strong Trend 26.63
UO(9)
Bearish 50.08
ROC(12)
Downtrend And Accelerating -4.16
WillR(14)
Neutral -72.29
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Listing Date
09 May, 2023(3 Years,
2 days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
